Objective: Recently, genome-wide association studies have identified 3 new susceptibility loci for Alzheimer's disease (AD), CLU, CR1, and PICALM. We leveraged available neuropsychological and autopsy data from 2 cohort studies to investigate whether these loci are associated with cognitive decline and AD neuropathology. Methods: The Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP) are longitudinal studies that enroll nondemented subjects and include annual clinical evaluations and brain donation at death. We evaluated CR1 (rs6656401), CLU (rs11136000), and PICALM (rs7110631) in 1,666 subjects. We evaluated associations between genotypes and rate of change in cognitive function as well as AD-related pathology. Lastly, we used pathway analysis to determine whether relationships between single nucleotide polymorphisms and cognitive decline are mediated through AD pathology. Results: Among our study cohort, the mean years of follow-up were 7.8 for ROS and 4.3 for MAP. Only the CR1 locus was associated with both global cognitive decline (p ¼ 0.011) and global AD pathology (p ¼ 0.025). More specifically, the locus affects the deposition of neuritic amyloid plaque (p ¼ 0.009). In a mediation analysis, controlling for amyloid pathology strongly attenuated the effect of the CR1 locus on cognitive decline. Interpretation: We found that common variation at the CR1 locus has a broad impact on cognition and that this effect is largely mediated by an individual's amyloid plaque burden. We therefore highlight 1 functional consequence of the CR1 susceptibility allele and generalize the role of this locus to cognitive aging in the general population. ANN NEUROL 2011;000:000-000 T he 20th century has witnessed a remarkable increase in the number and proportion of older persons, with wide-ranging health consequences, because older persons are at risk for chronic conditions that are relatively rare among the young. Alzheimer's disease (AD) in particular is among the most common and debilitating age-related conditions, causing progressive amnesia, dementia, and ultimately global cognitive failure and death. Genetic risk View this article online at wileyonlinelibrary.com.
factors have long been known to play an important role in the development of AD, but until recently, the only consistently validated susceptibility locus for sporadic late-onset AD was apolipoprotein E (APOE), with the e4 allele conferring an increased risk and the e2 allele a reduced risk. Using large cohorts of AD cases and controls, 2 independent genome-wide association studies recently identified 3 new loci, complement receptor 1 (CR1), clusterin (CLU), and the phosphatidylinositolbinding clathrin assembly protein (PICALM), with substantial evidence for association with AD, 1,2 and these loci have now been independently validated. 3 The majority of studies seeking to identify genetic variation responsible for AD have been case-control studies comparing persons with disease to those without. However, the dichotomous clinical outcome obscures the reality that AD develops slowly over years, and during this time affected individuals typically progress through a phase called mild cognitive impairment. 4 In fact, AD neuropathology, consisting of extracellular amyloid plaques and intracellular neurofibrillary tangles, is commonly found at autopsy in individuals without dementia proximate to death, and a substantial proportion of individuals with mild cognitive impairment meet pathological criteria for AD diagnosis. 5, 6 We and others have therefore proposed that intermediate cognitive and pathological traits might complement AD clinical diagnosis as an outcome phenotype for genetic association studies, in part by overcoming confounding due to phenotypic heterogeneity. 7, 8 Indeed, there is now substantial evidence that the APOE locus is associated with age-related cognitive decline as well as the accumulation of AD-related pathology in the general population, including individuals without dementia. 9, 10 Furthermore, in earlier work, the association of APOE with cognitive decline was shown to be mediated by an intermediate effect on amyloid burden. 10 It has been proposed that similar to APOE, the new AD susceptibility loci, CR1, CLU, and PICALM, might directly impact the accumulation of amyloid pathology, perhaps through participation in clearance of the A-beta peptide, which aggregates to form amyloid plaques. 1, 2 The Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP) are prospectively following >2,300 subjects without dementia at baseline, and include longitudinal clinical evaluation and brain donation at death. In this study, we leverage the wealth of neuropsychiatric and neuropathologic phenotypes available in ROS and MAP to assess whether these loci, like APOE, more generally influence age-related cognitive decline. Finally, we perform a functional genetic dissection to evaluate whether associations of these loci with cognition are mediated by an effect on AD neuropathology.
Subjects and Methods

Subjects
Subjects are participants from 2 longitudinal follow-up studies.
The ROS, started in 1994, enrolled Catholic priests, nuns, and brothers, aged !53 years from about 40 groups in 12 states. Since January 1994, 1,132 participants completed their baseline evaluation, of whom 1,001 were non-Hispanic white. The follow-up rate of survivors exceeds 90%, as does the autopsy rate (481 autopsies of 511 deaths, of whom 457 were non-Hispanic white). Participants were free of known dementia at enrollment, agreed to annual clinical evaluations, and signed both an informed consent and an Anatomic Gift Act form donating their brains at time of death. 11 A more detailed description of the ROS can be found in previously published literature.
11
The MAP, started in 1997, enrolled older men and women from assisted living facilities in the Chicago area with no evidence on dementia at baseline. Since October 1997, 1,285 participants completed their baseline evaluation, of whom 1,118 were non-Hispanic white. The follow-up rate of survivors exceeds 90%, and the autopsy rate exceeds 80% (336 autopsies of 411 deaths, of whom 320 were non-Hispanic white). Similar to ROS, participants agreed to annual clinical evaluations and signed both an informed consent and an Anatomic Gift Act form donating their brains, spinal cords, and selected nerves and muscles to Rush investigators at the time of death. 11, 12 More detailed descriptions of these studies can be found in previously published literature. 11, 12 Both ROS and MAP were approved by the institutional review board of Rush University Medical Center.
Genotyping
DNA was extracted from whole blood, lymphocytes, or frozen postmortem brain tissue. We used the single nucleotide polymorphisms (SNPs) outlined in recent publications 1,2 for CR1 (rs6656401) and CLU (rs136000). For PICALM, the published SNP (rs3851179) did not pass quality control (QC) in our dataset, so we used a SNP proxy, rs7110631, r 2 ¼ 0.75 with rs3851179 in HapMap subjects of European ancestry (http:// hapmap.ncbi.nlm.nih.gov/). Genotype data for rs6656401 (CR1), rs7110631 (PICALM), and rs11136000 (CLU) were extracted from a genome-wide dataset generated on the Affymetrix Genechip 6.0 platform at the Broad Institute's Center for Genotyping (n ¼ 1,204) or the Translational Genomics Research Institute (n ¼ 674). These 2 sets of data underwent the same QC analysis in parallel, and QC'ed genotypes were pooled. Only self-declared non-Hispanic Caucasians were genotyped, to minimize population heterogeneity. The PLINK toolkit (http://pngu.mgh.harvard.edu/$purcell/plink/) was used to implement our QC pipeline. We applied its standard quality control pipeline for subjects (genotype success rate >95%, Summary measures were created as previously described 12, 15, 23, 24 by converting each test into a Z score using the mean and SD from baseline evaluation of all participants and averaging the measure for each of the cognitive areas. Summary measures are beneficial for limiting the influence of outliers. For our analysis, at least half of the composite scores must be present for the summary measure to be valid.
Pathology Outcomes
Brain autopsies were performed for nearly all cases at 12 predetermined sites across the United States, including Rush University in Chicago. Autopsy procedures are described in detail in previously published literature. 11, 26, 27 We classified persons as having pathologic AD based on intermediate or high likelihood of AD by National Institute on Aging-Reagan criteria using Consortium to Establish a Registry for Alzheimer's Disease estimates of neuritic plaque density and Braak staging of neurofibrillary pathology, 28-30 as previously described. 11 The quantitative composite AD pathology score was based on counts of neuritic plaques and neurofibrillary tangles, as previously described. 31, 32 We standardized the raw counts by dividing each person's count by the standard deviation for that particular count and formed a global pathology summary score by averaging the standardized scores. In addition, separate summary measures of neurofibrillary tangles and neuritic and diffuse plaques were created in a similar fashion.
Statistical Analysis
Demographic characteristics of each cohort are described using means and standard deviations for continuous variables and frequency and proportions for categorical variables, including the SNPs of interest. Demographics and genotypic frequencies were compared across studies using 2 independent sample t tests and chi-square tests. General linear mixed models adjusting for age at enrollment, years of education, and sex were used to compare the rate of cognitive decline between genotypes. For all 3 SNPs, we initially used an additive model that examines the affect of each additional risk allele. Because this is a follow-up study to replicate previous findings by Harold et al 1 and Lambert et al, 2 we imposed a nominal threshold of p < 0.05 for significance in the primary analyses for association with global cognitive decline and global pathology in which the default additive model was tested. If a relationship was found at p < 0.10, we further examined the relationship using a dominant model comparing the homozygote for the nonrisk allele to the combined heterozygote and homozygote for the risk allele, or using a recessive model comparing the combined homozygote for the nonrisk allele and the heterozygote to the homozygote for the risk allele. We used these mixed models to plot the paths of change in each cognitive measure by genotype for our significant findings. Additional models were also run with further adjustment for APOE e4 allele. As a secondary analysis, logistic regression models adjusted for age at baseline, sex, and education were used to test whether the 3 SNPs were associated with any clinical diagnosis of AD after baseline. Linear regression and analysis of covariance (ANCOVA) models adjusted for age at death, years of education, and sex were used to assess the relationship between pathology measures and genotypes within the deceased participants. First, a linear regression model was used, and if a significant relationship was found at p < 0.10, an ANCOVA model was run where the adjusted mean pathology score is compared between each genotype, the p value testing if at least 1 mean is different. Lastly, 2 causal pathway analyses using Cooper's Local Causal Discovery algorithm 33 are performed by repeating the mixed models adjusting for AD pathology measures to determine whether the relationship between SNP and cognitive decline is mediated by pathology. All results were initially stratified by study and then combined. An interaction term was used to examine possible effect modification over time and determine whether effect sizes vary across study. All tests were performed using SAS software, version 9.2 (SAS Institute, Cary, NC).
Results
Demographics
Genotype data on 791 participants in ROS were available, and 326 (41%) of these subjects had neuropathologic data. Genotype data on 875 participants in MAP were available, and 227 (26%) of these subjects had neuropathology data. The mean (6standard deviation [SD]) age at enrollment for ROS and MAP participants was 76 (67) and 81 (67) years, respectively, and the mean (6SD) time of follow-up for ROS and MAP was 8 (65) and 4 (63) years, respectively. Although ROS and MAP differ significantly in demographic information, they do not differ in allele frequencies for the 3 SNPs considered in this analysis (p > 0.05 for all SNPs), and none of the interaction analyses were significant (all p > 0.01, with 21 tests performed), Because of this, we 
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combined the 2 studies to maximize the statistical power of our primary analyses. However, we also present the results from stratified analyses in Supplemental Tables 1  and 2 . In addition, when including a term for study in the models, we saw no change in our results. Thus, we removed the study term from the final models. This approach has been used previously 11 and is possible because of the extensive overlap in the information collected prospectively from the 2 cohorts and of their management by a single team of investigators. Demographic information on participants is presented in Table 1 . Within the combined cohort, 404 (24%) of the subjects fulfilled criteria for a diagnosis of AD dementia at some point during the follow-up time.
Cognitive Decline
For the CR1 locus, we see a significantly faster rate of decline in global cognition with each additional risk allele (rs6656401 A ) (p ¼ 0.011). In secondary analyses, this association with the CR1 locus is still present if we control for APOE e4 (p ¼ 0.02) ( Table 4 ).
For the PICALM locus, we saw suggestive evidence of association in the additive model for global cognition, with a faster rate of decline for each additional risk allele (rs7110631 G ) (p ¼ 0.10). In secondary analyses, the recessive model returns p ¼ 0.03 for global cognition (see Table  2 ). One interesting finding is in the stratified analyses (see Supplementary Table 1 ). The effect we see at the PICALM locus is driven primarily by the MAP cohort. Adjustment for APOE e4 genotype did not change the results in our combined analyses; however, it does affect the MAP-specific analysis. For MAP alone, we see a significant recessive relationship for rs7110631 GG We see no significant relationship between the rate of change in global cognitive performance and the CLU locus. Adjustment for APOE e4 genotype did not change the results of the CLU loci (see Table 2 ).
Pathology
We followed up our investigations of cognitive decline with an analysis of traits derived from our autopsy material (n ¼ 553). There is an association between the rs6656401 A risk allele in the CR1 locus and greater AD-related neuropathologic burden on autopsy using our default additive model for the effect of the risk allele (p ¼ 0.03) ( Table 3) . In this case, the small sample size precludes a powerful assessment of the minor (risk) allele homozygote class of subjects (rs6656401 AA ). Nonetheless, we observe a trend in global neuropathology scores when examining each genotype individually in secondary analyses, with the lowest score seen in rs6656401 GG class and increasing scores for each additional risk allele (see Table 3 ). When breaking down the global pathology score into its components, we see that the significant relationship between the CR1 locus and pathology is driven by an effect on diffuse and neuritic plaques (p ¼ 0.03 and p ¼ 0.01, respectively) but not neurofibrillary tangles (p ¼ 0.37). The APOE e4 allele does not modify the associations presented above (data not shown).
On the other hand, no significant differences were seen in analyses of our measure of global pathologic burden with the CLU and the PICALM loci (p ¼ 0.98 and p ¼ 0.34 respectively); this continues to hold true when controlling for the APOE e4 allele (data not shown). Exploratory analyses of the components of the global pathology score revealed no association between either loci and measures of amyloid deposition or neurofibrillary tangles (data not shown).
Pathway Analyses
Having independent associations of the CR1 loci with cognitive decline and AD-related neuropathology, we explored whether these associations were consistent with our putative causal chain linking genetic variation and cognitive dysfunction. For the pathway analyses, we examined cognitive decline as a function of the CR1 locus and measures of AD pathology in the same model. The results for CR1 are presented in Table 4 . For this analysis, we focus on the slope estimates of cognitive decline and whether controlling for global pathology attenuates the magnitude of the estimate of the risk allele's effect on the rate of global cognitive decline. The slope estimate (standard error) for the association of CR1 with the rate of global cognitive performance drops from À0.030 (0.016) in the model without global pathology to À0.017 (0.015) (a reduction of 43% in effect size) when we adjust for global pathology. A similar pattern is seen with our estimate of episodic memory decline, which drops from À0.025 (0.018) to À0.008 (0.017) after controlling for global pathology. This represents a 64% decrease in effect size for episodic memory decline (Supplementary Table 5 ). The decline in the estimates suggests that global pathology is in the pathway between rs6656401 A , the CR1 risk allele, and decline in global cognitive function. Looking at the components of our global pathology measure, we see that the effect of the rs6656401 A risk allele in the CR1 locus on cognitive performance is primarily mediated through an effect on neuritic plaques (37% decrease in effect size), with a more modest effect on diffuse plaques (20% decrease in effect size). In our dataset, neurofibrillary tangles have no affect on the correlation between rs6656401 A and cognitive decline (see Table 4 ).
Discussion
Three novel susceptibility loci have recently been proposed for AD, but additional studies are needed to confirm these findings and clarify how the risk alleles within these loci exert their effect. Here, we demonstrate that the risk allele within the CR1 locus is associated with both a greater burden of AD-related neuropathology and a faster rate of cognitive decline in an aging population that is nondemented at baseline. More specifically, our results suggest that the CR1 locus has an effect on almost all cognitive domains tested; its effect is not limited to episodic memory. Furthermore, our modeling suggests that this contribution to global cognitive dysfunction is mediated in large part (43% for global cognition and 64% for episodic memory) by an enhanced burden of AD-related neuropathology, particularly amyloid plaques. Nonetheless, our measure of global neuropathology does not fully capture the effect of the CR1 locus on cognitive function, suggesting that it may also have effects on different, as yet unrecognized mechanisms, or that measures of neuropathology that are molecularly specific may have stronger effects than those seen with histochemistry. Our results are therefore consistent with experiments in vitro and in model organisms that suggest a role for CR1 in clearance of amyloid plaques. 34 These results also establish clear hypotheses relating to the functional consequences of the CR1 risk allele that can now be explored further in a number of systems and raise the intriguing possibility that this variant may influence the success of different immunotherapies now being tested in AD.
The fact that we have performed these analyses in 2 large prospective cohorts of subjects who were nondemented on enrollment also generalizes the role of CR1; this locus, which was discovered in an AD susceptibility scan, may have a broader role in affecting cognitive function in older age. Indeed, we demonstrate that it does not have a predilection for affecting episodic memory; instead, it affects almost all of the cognitive domains that we have tested. It may therefore have a broader role in aging-related neurodegenerative processes. This is also supported by the persistence of the association if we restrict the analysis to cognitive assessments that are obtained from subjects who do not have a diagnosis of AD (see Supplementary Table 4) .
The other 2 loci that we tested in this study showed no significant evidence of association with either cognitive function or global pathology in our primary analyses. However, the PICALM locus displays suggestive evidence of association with cognitive decline. Given our sample size, we can exclude a strong effect of the PIC-ALM and CLU loci on our outcome measures, but it remains possible that more modest effects exist. These results are consistent with the findings by Guerreiro et al, 35 which showed no common coding variants at the CLU loci associated with AD. Neither the CLU nor the PICALM variants are likely to be the causal allele; they are merely the best surrogate marker tested so far. Thus, it is possible the true causal variant in these or the CR1 locus could have much stronger effects on our outcomes of interest. The PICALM analysis was also limited by the unavailability of the reported SNP (rs3851179) in our dataset; instead, we used a surrogate marker, rs7110631, which has an r 2 of 0.75 with rs3851179 in subjects of European ancestry in HapMap (http://hapmap.ncbi.nlm. nih.gov/). In modeling the causal chain of events, we took our analysis further and showed that, when controlling for global pathology, the strength of the relationship between CR1 and cognitive decline decreases. This suggests that global pathology plays an important role in the causal pathway between CR1 and cognitive decline.
When limiting our analysis to only those with autopsy data-thus decreasing our sample size-we found only borderline statistical significance with global cognition, which is probably due to limitations in statistical power. Nonetheless, we feel that because (1) we show a significant relationship between CR1 and the cognition measure when using the larger sample, and (2) the magnitude of the beta estimates clearly decreased when controlling for global pathology, this shows convincing evidence supporting a model in which global pathology mediates the effects of CR1 on cognition. Further work in model organisms will be necessary to test the hypothesis that alteration of CR1 function can yield to cognitive dysfunction that is mediated by an effect on amyloid pathology.
Our main analyses considered 3 loci and 2 outcomes, resulting in 6 different tests. Because our primary goal was to replicate previous findings by Lambert et al 2 and Harold et al, 1 we used a nominal level of significance of 0.05 and did not correct for multiple comparisons. We note, however, that our primary finding that CR1 is significantly associated with decline in global cognition under the dominant model still holds when ANNALS of Neurology comparing our resulting p value to a Bonferroni-corrected p value of 0.008 ( ¼0.05/6). This study has several strengths. First, both cohorts are rich in data, with high rates of follow-up and autopsy, thus decreasing bias. Second, the analysis was performed on a prospective cohort of older adults, all of whom were cognitively normal at the time of enrollment. Although this design may reduce our power to detect susceptibility genes associated with an earlier age at dementia onset due to differential survivor bias, it permits us to assess associations with cognitive decline and neuropathology unrelated to the subject selection biases in retrospective case-control studies. Third, the standardized nature of both the clinical and pathology procedures produced very similar and reliable measures between the cohorts and allowed us to combine the data and increase our statistical power. Fourth, this study complements and supports findings from a study of an independent group of neuropathologically verified cases and controls, which found associations between CR1 (as well as CLU and PICALM) and susceptibility to late-onset AD. 3 Finally,
we illustrate the advantages of detailed intermediate phenotypes in understanding the functional consequences of common variants associated with AD. In particular, we provide new insights about the neuropathological features underlying the association between CR1, age-related cognitive decline, and susceptibility to late-onset AD.
